Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2021.3547
Abstract: Importance Angiosarcoma is a rare sarcoma subtype with a poor outcome. Carotuximab plus pazopanib produced a median progression-free survival (PFS) of 7.8 months in pazopanib-naive patients with chemotherapy-refractory angiosarcoma in a phase 1/2 trial. Objective… read more here.
Keywords: pazopanib alone; trial; carotuximab plus; advanced angiosarcoma ... See more keywords
OER‐073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34403
Abstract: Angiosarcomas are rare mesenchymal sarcomas that can present as primary cutaneous or noncutaneous disease. They express a variety of vascular endothelial growth factor receptors. The authors hypothesized that the treatment of angiosarcoma with pazopanib, a… read more here.
Keywords: oer 073; pazopanib; 073 multicenter; multicenter phase ... See more keywords
Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia
Sign Up to like & getrecommendations! Published in 2021 at "Angiogenesis"
DOI: 10.1007/s10456-021-09807-4
Abstract: Hereditary hemorrhagic telangiectasia (HHT) is a rare angiogenic disorder causing chronic gastrointestinal bleeding, epistaxis, and severe anemia. Pazopanib is an oral multi-kinase angiogenesis inhibitor with promise to treat bleeding in HHT. We analyzed outcomes of… read more here.
Keywords: pazopanib; severe bleeding; hereditary hemorrhagic; transfusion dependent ... See more keywords
Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib.
Sign Up to like & getrecommendations! Published in 2017 at "Lung cancer"
DOI: 10.1016/j.lungcan.2016.12.008
Abstract: OBJECTIVES To investigate the effect of pazopanib on different CTCs subpopulations in patients with recurrent SCLC and evaluate their clinical relevance. METHODS Peripheral blood was obtained before the administration of pazopanib (n=56 patients), after the… read more here.
Keywords: pazopanib; number; ctcs patients; lung cancer ... See more keywords
A phase II study on the neo-adjuvant combination of pazopanib and radiotherapy in patients with high-risk, localized soft tissue sarcoma
Sign Up to like & getrecommendations! Published in 2021 at "Acta Oncologica"
DOI: 10.1080/0284186x.2021.1971294
Abstract: Abstract Purpose A prior phase I study showed that the neo-adjuvant combination of pazopanib and radiotherapy was well tolerated, and induced promising pathological responses in soft-tissue sarcoma patients. Results of the subsequent prospective, multicenter phase… read more here.
Keywords: tissue sarcoma; combination; pazopanib; neo adjuvant ... See more keywords
Multicenter real-world experience of the clinical efficacy and tolerance of pazopanib in high-risk pediatric solid tumors (PazoPed).
Sign Up to like & getrecommendations! Published in 2023 at "Pediatric hematology and oncology"
DOI: 10.1080/08880018.2023.2182854
Abstract: Pazopanib, a receptor tyrosine kinase inhibitor, exhibits anti-tumor activity in adult bone and soft-tissue sarcomas (STS), but has not yet been approved for pediatric tumors. The primary objective was to evaluate pazopanib efficacy when used… read more here.
Keywords: pazopanib; multicenter real; efficacy; solid tumors ... See more keywords
Drug review: Pazopanib
Sign Up to like & getrecommendations! Published in 2018 at "Japanese Journal of Clinical Oncology"
DOI: 10.1093/jjco/hyy053
Abstract: Pazopanib (Votrient®) is an oral small-molecule multi-kinase inhibitor that primarily inhibits vascular endothelial growth factor receptor-1, -2 and -3, platelet endothelial growth factor receptor-α, and -β, and the stem-cell factor receptor c-kit. In preliminary experiments… read more here.
Keywords: pazopanib; endothelial growth; growth factor; factor receptor ... See more keywords
709: SAFETY OF 4-FACTOR PCC FOR REVERSAL OF FXA INHIBITORS VERSUS WARFARIN IN NEUROCRITICAL CARE PATIENTS
Sign Up to like & getrecommendations! Published in 2019 at "Critical Care Medicine"
DOI: 10.1097/01.ccm.0000551460.73571.35
Abstract: Learning Objectives: Posterior reversible encephalopathy syndrome (PRES) is a state of hyperperfusion and endothelial dysfunction that can present with headache, seizure, encephalopathy, visual impairment, severe hypertension, and cerebral edema on magnetic resonance imaging (MRI). We… read more here.
Keywords: pazopanib; pcc reversal; safety factor; 709 safety ... See more keywords
Pazopanib restricts small cell lung cancer proliferation via reactive oxygen species‐mediated endoplasmic reticulum stress
Sign Up to like & getrecommendations! Published in 2022 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.14543
Abstract: Pazopanib is an approved multitarget anticancer agent for soft tissue sarcoma (STS) and renal cell carcinoma (RCC), which is also under clinical investigation for other malignancies, including small cell lung cancer (SCLC). However, the potential… read more here.
Keywords: lung cancer; cell; pazopanib; small cell ... See more keywords
Phase II trial of pazopanib in patients with metastatic or unresectable chemoresistant sarcomas: A Japanese Musculoskeletal Oncology Group study
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Science"
DOI: 10.1111/cas.14542
Abstract: Alveolar soft part sarcoma (ASPS), epithelioid sarcoma (ES), and clear cell sarcoma (CCS) are known to be chemoresistant tumors. The aim of this study was to investigate the effect of pazopanib on these chemoresistant tumors.… read more here.
Keywords: pazopanib; japanese musculoskeletal; musculoskeletal oncology; oncology ... See more keywords
Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-17-0272
Abstract: Purpose: Pazopanib, a multireceptor tyrosine kinase inhibitor targeting primarily VEGFRs1–3, is approved for advanced soft tissue sarcoma (STS) and renal cell cancer. Downstream of VEGFR, trametinib is an FDA-approved MEK inhibitor used for melanoma. We… read more here.
Keywords: pazopanib; combination; inhibitor; advanced soft ... See more keywords